Skip navigation
Watchlist Sponsored By :

Current DateTime: 08:15:26 11 Jul 2009
LinksList Documentid: 24355697
  • Highest Grossing Movies

      What are the highest grossing movies of all time, adjusted for inflation? Click ahead to find out!

  • Most Expensive Places To Live

      Each year, Mercer Consulting assembles its ranking of the most expensive places to live. Mercer compiles information from 143 cities worldwide.

  • Recession-Resistant US Cities

      Some cities have been hit much harder than others during the recession. Here are the metro areas faring the best.


Current DateTime: 08:15:26 11 Jul 2009
LinksList Documentid: 24890560
  • Boom, Bust and Blame

      The inside story of the economic crisis that has gripped the entire world.

  • E3: Gaming's Cutting Edge

      North America's premier computer and video game trade show draws tens of thousands of professionals to experience the future of interactive entertainment.

  • The Fall of GM

      A look into the fall of General Motors as the automaker heads toward bankruptcy and an effective nationalization.

Glaxo to Buy Sirtris Pharmaceuticals for $22.50 a Share
By: Reuters | 22 Apr 2008 | 05:09 PM ET
Text Size

GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.

Glaxo said it will commence a cash tender offer for all outstanding shares of Sirtris [SIRT  Loading...      ()   ], at $22.50 per share.

That reflects a 84 percent premium to their closing price of $12.23 Tuesday.

"Through the acquisition of Sirtris, GlaxoSmithKline will significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that are believed to be involved in the aging process," the companies said in a joint release.

The companies said Sirtris has initially been exploring whether, by activating the enzymes, its experimental drugs can effectively treat Type 2 diabetes -- the most common form of diabetes which is highly linked to obesity and generally develops in adulthood.

Glaxo said it plans to retain all Sirtris employees, which will continue to operate in Cambridge, Massachusetts as an independent unit.

"Modulation of this family of enzymes is a potentially transformative science that could address diseases associated with metabolism and aging such as diabetes, muscle wasting, and neurodegeneration," Moncef Slaoui, Glaxo's research chief, said in the release.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon


Current DateTime: 01:07:47 11 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:07:47 11 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 07:18:53 11 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:06:09 11 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters